A Phase Ⅱ Study of MESA Chemotherapy for Newly Diagnosed, Relapsed or Refractory Extranodal Natural

• 作 者: RongLiang[1]Guang-xunGao[1]Jie-pingChen[2]Ji-shiWang[3]Xiao-minWang[4]YunZeng[5]Qing-xianBai[1]TaoZhang[1]LanYang[1]Bao-xieDong;Hong-taoGu;Mi-miShu;Cai-xiaHao;NaZhang;Jian-hongWang;Xie-qunChen;
• 机 构: Department of Hematology, Xijing Hosptial, Fourth Military Medical University, 710032
• 出 处: 中华医学会第十三次全国白血病·淋巴瘤学术会议
• 发表日期: 2015年期

　　Purpose/Background: The nasal type of extranodal natural killer NK/T-cell lymphoma (NKTCL) is a rare aggressive lymphoma with poor prognosis.To explore a more effective and feasible treatment, we conducted a phase Ⅱ study of the steroid (Methotrexate, etoposide, dexamethasone, Polyehylene glycolasparaginase, MESA) regimen and investigated its efficacy and toxicity.(ClinicalTrialNCT01933282).